Detalhe da pesquisa
1.
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Clin Infect Dis
; 75(3): 390-398, 2022 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34940806
2.
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
J Infect Dis
; 212(1): 18-27, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25395187
3.
Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
Clin Infect Dis
; 61(3): 313-23, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25870329
4.
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.
Hum Vaccin Immunother
; 18(6): 2126253, 2022 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368038
5.
Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
Hum Vaccin Immunother
; 15(2): 444-451, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30303436
6.
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Hum Vaccin Immunother
; 15(3): 575-583, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30648932
7.
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
Hum Vaccin Immunother
; 13(9): 2065-2071, 2017 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881165
8.
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6-17 Years of Age in India: An Open-label Trial.
Pediatr Infect Dis J
; 36(11): e283-e285, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28719496
9.
A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.
Vaccine
; 35(15): 1926-1935, 2017 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28262330
10.
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Vaccine
; 34(30): 3454-62, 2016 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27155493
11.
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
AIDS
; 29(11): 1345-54, 2015 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25888646
12.
Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico.
Clin Vaccine Immunol
; 22(2): 185-92, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25499011